



Speed to Biosimilars Market: How Digital Transformation Helps Win the Race

What to expect

With the global market for biosimilar drugs expanding rapidly, this white paper examines the importance for Indian pharmaceutical companies to effectively use digital tools to ensure they can conduct comprehensive, rapid data analysis throughout the path to market:

- See how data can help determine which biosimilars hold the most potential.
- Learn how digital tools can help break down the silos within a pharma organization and lead to better results.
- Discover what is required to complete the digital transformation of your enterprise so R&D can become more effective.

The biosimilar race

The race is competitive. The prize is huge.

But you can't win without your entire organization pulling in one direction and, if you have not completed your digital transformation journey, the benefits of enterprise-wide collaboration and data driven insights will continue to elude you.

The race is to get to market with biosimilar drugs ahead of the numerous other India-based pharma companies striving to do the same. Following the success of biologics, biosimilars offer a cost effective alternative to the high price point of patent protected, first-generation drugs. While generics must be identical in chemical composition to the original drug, biosimilars—which are far more complex—must be “highly similar” to another biological medicine in terms of structure, biological activity, and efficacy, safety, and immunogenicity profile.

The prize for overcoming the complexities of effective biosimilar scale-up is leadership of a sector that is undergoing a compound annual growth rate (CAGR) of more than 16 percent and is expected to be worth US\$2.2 billion by 2025¹. And beyond a lucrative position in the burgeoning Indian market is the opportunity to compete effectively in a global biosimilars market that has a CAGR of approximately 30.9 percent and may reach a valuation of as much as US\$60 billion by 2025². Since 2000, when the first Indian biosimilar was approved, the number that have successfully reached the market exceeds 95.




Figure 2: Leveraging Revvity Signals' technology for faster data insights and decision making in biosimilars development

For any organization hoping to compete, the essential keys to success are effective, forward-looking management, control, and data analysis. It is no exaggeration to state that data is the fuel that will make India's biosimilar hopefuls serious contenders in this race. Conversely, ineffective collaboration will condemn potential competitors to the status of also-rans.



revvitysignals.com
 940 Winter Street
 Waltham, MA 02451 USA
 P: (800) 762-4000 (+1) 203-925-4602

[LinkedIn](#) Revvity Signals
 [Facebook](#) RevvitySignalsSoftware
 [Instagram](#) revvitysignals
[YouTube](#) Revvity_Signals
 [Twitter](#) RevvitySignals

Copyright ©, Revvity, Inc. All rights reserved. Revvity® is a registered trademark of Revvity, Inc. All other trademarks are the property of their respective owners.